2-Fluor-4-methyl-Δ²-pentensaeure | 687-49-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-Fluor-4-methyl-Δ²-pentensaeure
• 英文别名: 2-Fluor-4-methylpent-2-ensaeure；2-Fluoro-4-methylpent-2-enoic acid；2-fluoro-4-methylpent-2-enoic acid
• CAS: 687-49-0
• 化学式: C₆H₉FO₂
• 分子量: 132.135
• InChiKey: VLTPEXOVJIWAIE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-Fluor-4,5-dioxo-2-isopropyl-tetrahydrofuran-carbonsaeure-(3)-ethylester 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 生成 2-Fluor-4-methyl-Δ²-pentensaeure
  参考文献：
  名称：

  Machleidt,H.; Wessendorf,R., Justus Liebigs Annalen der Chemie, 1964, vol. 674, p. 1 - 10

  摘要：

  DOI：

文献信息

• COMPOSITIONS COMPRISING CROSSLINKED CATION-BINDING POLYMERS AND USES THEREOF
  申请人：Relypsa, Inc.

  公开号：US20150183908A1

  公开（公告）日：2015-07-02

  The present disclosure relates generally to crosslinked cation-binding polymers comprising monomers containing carboxylic acid groups and pKa decreasing groups, wherein the polymer contains i) calcium cations that are counterions to about 5% to about 75% of the carboxylic acid groups in the polymer; or ii) calcium cations and magnesium cations that are counterions to about 5% to about 75% of the carboxylic acid groups in the polymer, wherein the magnesium cations are counterions to no more than about 35% of the carboxylate groups in the polymer. The present disclosure also relates to methods of preparation of the poly mers, and compositions, formulations, and dosage forms containing the polymers, and methods of using the polymers, compositions, formulations, and/or dosage forms to treat various diseases or disorders.

  本公开涉及交联阳离子结合聚合物，该聚合物包含含有羧酸基和pKa降低基的单体，其中聚合物包含i）钙阳离子，其是聚合物中约5％至约75％的羧酸基的对离子；或ii）钙阳离子和镁阳离子，其是聚合物中约5％至约75％的羧酸基的对离子，其中镁阳离子对聚合物中的羧酸盐基不超过约35％。本公开还涉及聚合物的制备方法，以及含有聚合物的组合物、配方和剂量形式，以及使用聚合物、组合物、配方和/或剂量形式治疗各种疾病或障碍的方法。
• 784. Organic fluorine compounds. Part XXV. Further reaction of aldehydes with diethyl fluoro-oxaloacetate
  作者：Ernst D. Bergmann、I. Shahak

  DOI：10.1039/jr9610004033

  日期：——
• COMPOSITIONS COMPRISING CROSSLINKED CATION-BINDING POLYMERS
  申请人：Relypsa, Inc.

  公开号：EP2874633A1

  公开（公告）日：2015-05-27
• [EN] COMPOSITIONS COMPRISING CROSSLINKED CATION-BINDING POLYMERS<br/>[FR] COMPOSITIONS COMPRENANT DES POLYMÈRES RÉTICULÉS DE LIAISON À DES CATIONS
  申请人：SORBENT THERAPEUTICS INC

  公开号：WO2014015240A1

  公开（公告）日：2014-01-23

  The present disclosure relates generally to compositions comprising a crosslinked cation-binding polymer comprising monomers containing carboxylic acid groups and pKa decreasing groups, including electron-withdrawing substituents such as halide atoms (e.g., fluorine), and a base, wherein the polymer optionally contains less than about 20,000 ppm of non-hydrogen cations, and wherein the base is present in an amount sufficient to provide from about 0.2 equivalents to about 0.95 equivalents of base per equivalent of carboxylic acid groups in the polymer. The present disclosure also relates to methods of preparation of said compositions and methods of using said compositions to treat various diseases or disorders.
• [EN] COMPOSITIONS COMPRISING CROSSLINKED CATION-BINDING POLYMERS<br/>[FR] COMPOSITION COMPRENANT DES POLYMÈRES RÉTICULÉS À LIAISON CATIONIQUE
  申请人：SORBENT THERAPEUTICS INC

  公开号：WO2014015244A1

  公开（公告）日：2014-01-23

  The present disclosure relates generally to crosslinked cation-binding polymers comprising monomers containing carboxylic acid groups and pKa decreasing groups, wherein the polymer contains i) calcium cations that are counterions to about 5% to about 75% of the carboxylic acid groups in the polymer; or ii) calcium cations and magnesium cations that are counterions to about 5% to about 75% of the carboxylic acid groups in the polymer, wherein the magnesium cations are counterions to no more than about 35% of the carboxylate groups in the polymer. The present disclosure also relates to methods of preparation of the polymers, and compositions, formulations, and dosage forms containing the polymers, and methods of using the polymers, compositions, formulations, and/or dosage forms to treat various diseases or disorders.